Search research articles
Contact Us
Filters
Showing results (151-160 of 164) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Nature Cancer
|
February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.
Science Translational Medicine
|
April 12, 2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
Jeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, et al.
Nature Communications
|
January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
Gail D Lewis, Guangmin Li, Jun Guo, et al.
The New England Journal of Medicine
|
August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Adrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Cancer Treatment Reviews
|
May 21, 2019
Improving attribution of adverse events in oncology clinical trials
Goldy C George, Pedro C Barata, Alicyn Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Timothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
The New England Journal of Medicine
|
March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Wungki Park, Anup Kasi, Alexander I Spira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Adrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 164) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Nature Cancer
|
February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.
Science Translational Medicine
|
April 12, 2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
Jeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, et al.
Nature Communications
|
January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
Gail D Lewis, Guangmin Li, Jun Guo, et al.
The New England Journal of Medicine
|
August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Adrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Cancer Treatment Reviews
|
May 21, 2019
Improving attribution of adverse events in oncology clinical trials
Goldy C George, Pedro C Barata, Alicyn Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Timothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
The New England Journal of Medicine
|
March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Wungki Park, Anup Kasi, Alexander I Spira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Adrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Page
of 17